Krystof S Bankiewicz
Overview
Explore the profile of Krystof S Bankiewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
3801
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barker R, Saarma M, Svendsen C, Morgan C, Whone A, Fiandaca M, et al.
J Parkinsons Dis
. 2025 Feb;
14(8):1659-1676.
PMID: 39957193
In 2023, a workshop was organized by the UK charity Cure Parkinson's with The Michael J Fox Foundation for Parkinson's Research and Parkinson's UK to review the field of growth...
2.
Heiss J, Ray-Chaudhury A, Kleiner D, Ehrlich D, Scott G, Edwards N, et al.
Mov Disord
. 2024 May;
39(8):1412-1417.
PMID: 38718138
Objective: Gene therapy by convection-enhanced delivery of type 2 adeno-associated virus-glial cell derived neurotrophic factor (AAV2-GDNF) to the bilateral putamina seeks to increase GDNF gene expression and treat Parkinson's disease...
3.
Ford M, George B, Van Laar V, Holleran K, Naidoo J, Hadaczek P, et al.
Nat Med
. 2023 Aug;
29(8):2030-2040.
PMID: 37580533
Alcohol use disorder (AUD) exacts enormous personal, social and economic costs globally. Return to alcohol use in treatment-seeking patients with AUD is common, engendered by a cycle of repeated abstinence-relapse...
4.
Rocco M, Akhter A, Ehrlich D, Scott G, Lungu C, Munjal V, et al.
Mol Ther
. 2023 Apr;
31(7):2296.
PMID: 37098347
No abstract available.
5.
Rocco M, Akhter A, Ehrlich D, Scott G, Lungu C, Munjal V, et al.
Mol Ther
. 2022 Aug;
30(12):3632-3638.
PMID: 35957524
Direct putaminal infusion of adeno-associated virus vector (serotype 2) (AAV2) containing the human glial cell line-derived neurotrophic factor (GDNF) transgene was studied in a phase I clinical trial of participants...
6.
Christine C, Richardson R, Van Laar A, Thompson M, Fine E, Khwaja O, et al.
Neurology
. 2021 Oct;
98(1):e40-e50.
PMID: 34649873
Background And Objectives: To report final, 36-month safety and clinical outcomes from the PD-1101 trial of NBIb-1817 (VY-AADC01) in participants with moderately advanced Parkinson disease (PD) and motor fluctuations. Methods:...
7.
Van Laar A, Van Laar V, San Sebastian W, Merola A, Elder J, Lonser R, et al.
J Parkinsons Dis
. 2021 Aug;
11(s2):S173-S182.
PMID: 34366374
At present there is a significant unmet need for clinically available treatments for Parkinson's disease (PD) patients to stably restore balance to dopamine network function, leaving patients with inadequate management...
8.
Pearson T, Gupta N, San Sebastian W, Imamura-Ching J, Viehoever A, Grijalvo-Perez A, et al.
Nat Commun
. 2021 Jul;
12(1):4251.
PMID: 34253733
Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare genetic disorder characterized by deficient synthesis of dopamine and serotonin. It presents in early infancy, and causes severe developmental disability and...
9.
Saha K, Sontheimer E, Brooks P, Dwinell M, Gersbach C, Liu D, et al.
Nature
. 2021 Apr;
592(7853):195-204.
PMID: 33828315
The move from reading to writing the human genome offers new opportunities to improve human health. The United States National Institutes of Health (NIH) Somatic Cell Genome Editing (SCGE) Consortium...
10.
Terse P, Kells A, Noker P, Wright J, Bankiewicz K
Int J Toxicol
. 2020 Nov;
40(1):4-14.
PMID: 33131343
Glial cell line-derived neurotrophic factor (GDNF) is a potent neuroprotective biologic in Parkinson's disease models. Adeno-associated viral vector serotype 2 (AAV2)-human GDNF safety was assessed in rats treated with a...